Ken Griffin Immunic, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Immunic, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 600 shares of IMUX stock, worth $558. This represents 0.0% of its overall portfolio holdings.

Number of Shares

600

Previous 3,500 82.86%

Holding current value

$558

Previous $3,000 100.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$1.0 - $1.61 $239,757 - $386,008	-239,757 Reduced 99.88%	300 $0
Q3 2024 Nov 14, 2024	BUY	$1.08 - $1.95 $259,259 - $468,107	240,055 Added 0.0%	240,057 $396,000
Q1 2024 May 15, 2024	BUY	$1.14 - $1.53 $2 - $3	2 New	2 $0
Q2 2023 Aug 14, 2023	SELL	$1.33 - $2.51 $8,114 - $15,313	-6,101 Reduced 76.45%	1,879 $4,000
Q1 2023 May 15, 2023	SELL	$1.35 - $2.87 $23,252 - $49,432	-17,224 Reduced 68.34%	7,980 $11,000
Q4 2022 Feb 14, 2023	BUY	$1.13 - $10.8 $28,480 - $272,203	25,204 New	25,204 $35,000
Q2 2022 Aug 15, 2022	BUY	$3.13 - $12.25 $1.45 Million - $5.66 Million	462,178 Added 1344.48%	496,554 $1.72 Million
Q1 2022 May 16, 2022	SELL	$9.54 - $14.26 $97,651 - $145,965	-10,236 Reduced 22.94%	34,376 $389,000
Q4 2021 Feb 14, 2022	BUY	$7.34 - $10.25 $225,360 - $314,705	30,703 Added 220.74%	44,612 $426,000
Q2 2021 Aug 16, 2021	SELL	$11.76 - $16.85 $108,415 - $155,340	-9,219 Reduced 39.86%	13,909 $170,000
Q4 2020 Feb 16, 2021	SELL	$14.8 - $20.37 $73,630 - $101,340	-4,975 Reduced 17.7%	23,128 $353,000
Q3 2020 Nov 16, 2020	BUY	$11.74 - $22.0 $329,929 - $618,266	28,103 New	28,103 $522,000

Others Institutions Holding IMUX

# of Institutions

Shares Held

47M

Call Options Held

1.14M

Put Options Held

130K

View Full List

About IMMUNIC, INC.

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $28.4M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

More about IMUX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account